Real-world evidence on the safety and effectiveness of fingolimod in patients with multiple sclerosis from Taiwan.

CONCLUSION: Fingolimod 0.5 mg/day treatment with an average of 2 years of exposure was associated with a manageable safety profile, and maintained/improved effectiveness in RRMS patients from Taiwan.
PMID: 32669233 [PubMed - as supplied by publisher]

Source: J Formos Med Assoc - July 11, 2020 Category: General Medicine Authors: Yang CC, Ro LS, Tsai NW, Lin CC, Huang WN, Tsai CP, Lin TS, Su JJ, Huang CC, Lyu RK, Chen HH, Lee WJ, Chen PL, Yang A Tags: J Formos Med Assoc Source Type: research